FDA Requests Analyses, Inspection Fixes in CRL for Tumor Therapy

Drug GMP Report
A A
The FDA has rejected Advanced Accelerator Applications’ candidate for the treatment neuroendocrine tumors in adults, requesting that the company submit new analyses and correct manufacturing deficiencies.

To View This Article:

Login

Subscribe To Drug GMP Report